ABCL Shares Outstanding
Total shares outstanding each quarter, showing dilution from issuance or reduction from buybacks.
Shares Outstanding
Latest: 307M (2026Q2)
| Period | Value |
|---|---|
| 2020Q2 | 261M |
| 2020Q3 | 153M |
| 2021Q1 | 320M |
| 2021Q2 | 272M |
| 2021Q3 | 279M |
| 2021Q4 | 282M |
| 2022Q1 | 311M |
| 2022Q2 | 285M |
| 2022Q3 | 316M |
| 2022Q4 | 286M |
| 2023Q1 | 288M |
| 2023Q2 | 289M |
| 2023Q3 | 289M |
| 2023Q4 | 290M |
| 2024Q1 | 293M |
| 2024Q2 | 294M |
| 2024Q3 | 295M |
| 2024Q4 | 295M |
| 2025Q1 | 298M |
| 2025Q2 | 299M |
| 2025Q3 | 299M |
| 2025Q4 | 299M |
| 2026Q1 | 303M |
| 2026Q2 | 307M |
* In some reporting periods, diluted weighted-average shares are used instead of period-end shares outstanding. Please verify individual figures against the company's SEC filings.
Other Indicators
Other ABCL Charts
More quarter-by-quarter fundamentals for AbCellera Biologics Inc.
1 / 8
Revenue
EPS
Free Cash Flow
FCF Margin
P/E Ratio
Cumulative FCF
Total Assets
Rule of 40
Healthcare Comparison
1 / 3
Shares Outstanding
Shares Outstanding
Shares Outstanding
Latest Shares Outstanding: 307M (2026Q2); +2.7% YoY; +11.9% CAGR since 2020Q1 (6.25y).
Across the 25 quarters from 2020Q1 to 2026Q2, Shares Outstanding ranged from 152M in 2020Q1 to 320M in 2021Q1.
Chart and table show the latest 24 of 25 quarters.